TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02119286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The matching placebo DPI identical in appearance to the inhaler containing active study medication.
Study: NCT00554307

Intervention type: DEVICE
Intervention: INVOS Cerebral/Somatic oximeter
Description: Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.

Intervention type: DEVICE
Intervention: INVOS Cerebral/Somatic oximeter
Description: Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.

Intervention type: DEVICE
Intervention: INVOS Cerebral/Somatic oximeter
Description: Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
Study: NCT02067429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limbal Relaxing Incisions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Intraocular Lens
Study: NCT04076384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Determination
Description: Structured team-based consultations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard consultations
Study: NCT02390141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP4207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04271020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroLift
Description: The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
Study: NCT02955017

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional follow_up
Description: * Multidisciplinary support with educational face to face family based intervention at 6, 9 and 12 months after inclusion.~* Two days of a complete medical check at 9 and 15 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: distance follow-up new technologies
Description: * Multidisciplinary support with long distance monitoring Mobile apps.~* Two days of a complete medical check at 9 and 15 months
Study: NCT02852642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Plyometric training
Study: NCT00186758

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.~Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.~Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -
Study: NCT03449836

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius 24SMBc + Strept. oralis 89a
Description: nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone + mometasone
Description: nasal spray based on fluticasone + mometasone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: nasal spray based on isotonic solution
Study: NCT00429156

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home non-invasive ventilation
Description: Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Home non-invasive ventilation (sham)
Description: Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
Study: NCT04191837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure treatment group
Description: Subjects in the self-administered acupressure exercise group will receive two training sessions (2 hours each, 1-week apart). The self-administered acupressure treatment protocol was developed based on Chinese medicine meridian theory by previous studies and modified. The acupoints are indicated for knee pain and have been commonly used and tested for feasibility in pilot study. The training will be conducted in a group format with 4-6 subjects per group. Each subject will then receive a handout and an acupressure log. They will be told to perform the self-acupressure twice per day for 12 weeks.The capability of participants for self-administered acupressure will be inspected by the instructor with a competency checklist in each session. And a demonstration video will be sent to the participants via WhatsApp for their reference at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee health education control group
Description: Subjects in the health education control group will receive knowledge related to knee OA symptom management. The health education will be conducted in a talk format for 2 hours for two sessions. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR and reviewed. Subjects in knee health education group will be told to follow the knee health instruction for 12 weeks.
Study: NCT01770392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: single dose administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: single dose once daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: single dose administration
Study: NCT03858192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal surgery procedure
Description: Elective admission for colorectal surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery
Description: Emergency admission necessitating emergency surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Treatment for infection and reason for admission
Study: NCT02434432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy selected by mothers
Description: mothers' choice of music

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music therapy recorded lullaby
Description: recorded lullaby
Study: NCT04350320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Tablets
Description: standard therapy for COVID-19 according to the stablished hospital protocols.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy for COVID-19 according to the stablished hospital protocols.
Description: standard therapy for COVID-19 according to the stablished hospital protocols.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy for COVID-19 according to the stablished hospital protocols.
Description: standard therapy for COVID-19 according to the stablished hospital protocols.
Study: NCT03191110

Intervention type: OTHER
Intervention: No intervention: observational study
Study: NCT02775708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillcam endoscopy system
Study: NCT00939120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4mg
Description: 1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-randomization Dutasteride
Description: All participants were on Dutasteride 0.5mg orally once daily prior to randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pre-randomization Dutasteride
Description: All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
Study: NCT03446911

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SABR
Description: Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: SABR + pembrolizumab
Description: Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy + 2 rounds of pembrolizumab
Study: NCT04145583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole +HSK3486
Description: Sequence 2: voriconazole：Day 1,400mg，BID；Day 2--Day 6,200mg，BID；200 mg of voriconazole were taken orally in the morning on an empty stomach of Day 7; followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
Study: NCT02017886

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri DSM 17938/ATCC PTA
Description: L. reuteri DSM 17938/ATCC PTA twice daily for three weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily for three weeks
Study: NCT03248050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacy encouraged to promote call centre use to clients
Description: The details of the intervention will be finalised following an intervention design workshop. The main components will be: Provision of materials with the MSZ call centre number on for pharmacy workers to give women buying MA medications to call the number for free, confidential advice on how to use the pills before they take them; incentives; monthly monitoring visits.
Study: NCT01874873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Study: NCT02766595

Intervention type: OTHER
Group type: OTHER
Intervention: hyperventilation while sitting up during routine EEG
Description: Child will be asked to perform hyperventilation while lying down as well as while sitting up
Study: NCT03461185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGFR-TK Inhibitor
Description: EGFR-TKIs include but are not limited erlotinib, gefitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Description: EGFR-TKIs include but are not limited erlotinib, gefitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Angiogenic Drugs
Description: Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib
Study: NCT03255811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib mesylate tablets treatment and to maintain the actual benefit in progression free survival.
Study: NCT04188002

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention Physical Activity
Description: 4 tailored newsletters focused on improving healthy diet and physical activity delivered at weekly intervals.
Study: NCT04770688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib, 80mg, QD, p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: (Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle.
Study: NCT01543919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study: NCT04188002

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: 4 non-tailored newsletters focused on issues relevant to cancer survivors (e.g. returning to work)
Study: NCT01543919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study: NCT03292393

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medication adherence assessment
Description: Participants will be informed that they will receive and learn how to use eCap, a medication event monitoring system that participants will return after completing the study. The project nursing student will count the number of pills the participant currently has and make a record of it on the Data Collection form.The participant will provide the project nursing student with his/her antihypertension prescription records so that the dosage amount and number of pills can be recorded on the Data Collection form.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medication adherence assessment
Description: Participants will be informed that they will receive and learn how to use eCap, a medication event monitoring system that participants will return after completing the study. The project nursing student will count the number of pills the participant currently has and make a record of it on the Data Collection form.The participant will provide the project nursing student with his/her antihypertension prescription records so that the dosage amount and number of pills can be recorded on the Data Collection form.
Study: NCT01324687

Intervention type: OTHER
Intervention: Telemedicine care
Description: Availability of telemedicine
Study: NCT04197024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise capacity test
Description: Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm). Heart rate (HR) will be continuously recorded using a monitor Polar H10.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise capacity test
Description: Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm). Heart rate (HR) will be continuously recorded using a monitor Polar H10.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise capacity test in virtual reality
Description: Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm).Heart rate (HR) will be continuously recorded using a monitor Polar H10. VR HTC Vive Pro goggles along with VR health care (aerobic exercise) VR Cycling software will be used for stimulation throughout the duration of the test. The HTC Vive Tracker device will be also use to link images in virtual reality with the pedal speed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise capacity test in virtual reality
Description: Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm).Heart rate (HR) will be continuously recorded using a monitor Polar H10. VR HTC Vive Pro goggles along with VR health care (aerobic exercise) VR Cycling software will be used for stimulation throughout the duration of the test. The HTC Vive Tracker device will be also use to link images in virtual reality with the pedal speed.
Study: NCT00444470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Eligible patients who have consented to be in the study and have been randomised to be in Arm A will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo.
Study: NCT03543670

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oncoxin-Viusid
Description: Support treatment with Oncoxin-Viusid (75mL/day) during chemotherapy/Radiotherapy until two weeks after (a total of 8 months).
Study: NCT04016688

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB and TAP block
Description: bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.5 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB and TAP block
Description: bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.5 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side.
Study: NCT00970268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
Study: NCT01106482

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serology blood draw
Description: Blood draw only, no vaccine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serology blood draw
Description: Blood draw only, no vaccine
Study: NCT01476735

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individual preparation for colonoscopy
Description: The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individual preparation for colonoscopy
Description: The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy
Study: NCT01475058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes
Description: Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV